China Fires Scientists After Gene-Editing Trial Death
China has sacked two scientists after a six-year-old girl died during an experimental gene-editing trial, following an investigation that found safety warnings from animal tests were ignored and the child’s death was never disclosed in the published research.
What the investigation found
A task force set up by the Shanghai municipal government announced its findings on Friday, 13 November, through Chinese state media. The investigation found that the research team failed to follow regulations and overlooked warning signs in a safety report from monkey tests completed in February 2025, a month before the girl received the therapy.
The lead researcher, neuroscientist Zilong Qiu, has been dismissed from his post as deputy director of the Songjiang Research Institute, which is affiliated with Shanghai Jiao Tong University School of Medicine. A second researcher, Kan Yang, an associate researcher at Xinhua Hospital, was also dismissed. Both have been barred for five years from leading or taking part in state science and technology projects and from awards, and their names have been entered in a national database of serious research-integrity violations.
The head of clinical research at Xinhua Hospital was also removed from his research leadership post, demoted two grades and barred for five years from promotion, state science projects, awards and taking graduate students.
The trial and the child’s death
The girl, aged six, had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder for which there is no effective treatment. Her family first approached Qiu’s team in July 2023. The therapy used a base editor, a CRISPR-derived tool that rewrites a single letter of DNA, carried by adeno-associated virus particles injected into the fluid around her spine so it could travel to her brain.
Xinhua Hospital’s ethics committee approved the study on 2 January 2025. The girl received the injection on 24 March 2025 and died on 31 March, a week later, despite resuscitation efforts. An emergency ethics review on 2 April concluded that she had died of thrombotic microangiopathy, a complication of the gene therapy, and ordered the study stopped.
The investigation also found that the consent form signed on 20 February mentioned possible serious complications but did not prominently warn of death, and that the team took money and gifts from the family. The researchers also failed to promptly disclose the monkey safety report and the girl’s death when they published their research in the journal Nature on 18 February 2026.
How the death came to light
The girl’s death only became public in July 2026, when the journal Science and the website Retraction Watch jointly reported that she had been the first person in the world to receive a gene-editing therapy directed at the brain. Nature placed an editor’s note on the paper on 29 July, and the trial’s registry entry now lists the study as terminated because its single participant died of a serious adverse event assessed as definitely related to the study drug.
Experts quoted in the coverage said the huge viral dose used to deliver the therapy, rather than the base editing itself, was the more likely cause of death.
Wider impact on Chinese research
The case has put China’s fast-track pathway for investigator-initiated trials under scrutiny. The trial was conducted under that pathway, which lets doctors test some novel therapies after local review. New Chinese rules that took effect in May 2026 now limit such trials to top-tier hospitals, impose stricter manufacturing standards and toughen penalties for non-compliance.
Read our earlier health coverage https://ntmnews.online/?p=5610 and our report on rabies treatment in Sindh https://ntmnews.online/?p=5648 for more on health stories in the region.
The case follows the 2018 scandal involving biophysicist He Jiankui, who secretly created gene-edited babies and was later sentenced to three years in prison. Shanghai’s investigation team said the institutions involved, Shanghai Jiao Tong University School of Medicine and Xinhua Hospital, have also been reprimanded and told to examine their own practices.
Source: Nature, VnExpress, CBS News via Chinese state media — 16-17 November 2026